EUR/USD 1.15840
-0.071%
Gold 4365.73
0.869%
Oil 89.574
0.226%
USD/JPY 158.927
-0.778%
GBP/USD 1.34858
-0.217%
GBP/JPY 214.330
-0.989%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
Israeli Prime Minister Netanyahu: We can attack Iran at any time.On September 3, the Iranian Foreign Ministry issued a statement on September 2, local time, strongly condemning the US military action against Iran. The statement said the US attacked multiple demilitarized zones, ports, communication facilities, and other civilian infrastructure in the provinces of Khuzestan, Sistan-Baluchistan, Hormozgan, and Kerman, causing casualties and property damage. The statement said that a US attack on a wedding in Sirik district of Hormozgan province resulted in the deaths and injuries of more than 70 Iranians, most of whom were women and children. The Iranian Foreign Ministry stated that the actions violated basic principles of international law and international humanitarian law. The statement indicated that the Iranian armed forces, in accordance with the right of self-defense under the UN Charter, carried out a "defensive and deterrent strike" against US military bases that served as the starting point and logistical support for the US attacks on Iran. Iran also urged regional countries to prevent the US from using its territory and airspace to conduct military operations against Iran and called on the UN Security Council and the UN Secretary-General to fulfill their responsibilities to prevent further escalation of the situation.Israeli Prime Minister Netanyahu: If Iran chooses to attack us, they know it will be one of their final decisions.Spokesperson for the UN Secretary-General: The Secretary-General is concerned about reports of casualties from the US attack on Iran.The Mayor of Moscow: Three more drones flying towards Moscow were shot down today. This brings the total number of destroyed drones to 28.

Novavax Reduces Its Full-year Revenue Forecast Due to Sluggish Demand

Haiden Holmes

Nov 09, 2022 15:55

52.png


Novavax (NASDAQ:NVAX) decreased its full-year revenue guidance for the second time in three months on Tuesday as a result of a global supply glut in COVID-19 vaccine and declining demand.


The company now expects its annual revenues to fall within the lower half of its earlier forecast range of $2 billion to $2.3 billion.


Novavax reduced its revenue forecast for the year in August, since the business did not expect to sell any additional COVID-19 vaccine in the United States this year.


Filip Dubovsky, the chief medical officer of Novavax, stated on a conference call with investors that the company is "moving forward" with the development of a vaccine against Omicron sub variants BQ.1 and BQ.1.1, which would also be formulated as a bivalent vaccination with another coronavirus strain.


Dubovsky noted that Novavax intends to get the vaccine ready by the second quarter of 2019 in time for an expected surge in cases in the southern hemisphere.


Novavax stated Tuesday morning that its COVID-19 vaccine has been modified for the Omicron BA.


In advanced study, one variant generated a substantial immune response at the fourth dose, meeting the strain swift's main purpose.


The shares of the Maryland-based firm surged by nearly 1 percent in afternoon trading after the company reported third-quarter revenues that were above analyst projections.


Last week, Pfizer Inc. (NYSE:PFE) increased its annual COVID vaccination sales projection. After the government ceases buying doses and sales move to the private sector, the company intends to almost double the price of the vaccine injection in the United States in order to combat declining sales.


Even though more than 640 million COVID-19 doses have been distributed in the United States, just 43,540 Novavax vaccines have been delivered as of November 2, according to the most current government figures.


In October, the U.S. Food and Drug Administration authorized the COVID-19 vaccine as a booster for adults, in addition to its existing clearance as a primary two-shot regimen for those 12 and older.

Suggestion